ES2521674T3 - Métodos de tratamiento de hiperuricemia y estados patológicos asociados - Google Patents
Métodos de tratamiento de hiperuricemia y estados patológicos asociados Download PDFInfo
- Publication number
- ES2521674T3 ES2521674T3 ES09792556.4T ES09792556T ES2521674T3 ES 2521674 T3 ES2521674 T3 ES 2521674T3 ES 09792556 T ES09792556 T ES 09792556T ES 2521674 T3 ES2521674 T3 ES 2521674T3
- Authority
- ES
- Spain
- Prior art keywords
- patient
- hyperuricemia
- treatment
- methods
- pathological conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 3
- 229940116269 uric acid Drugs 0.000 abstract 3
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9702308P | 2008-09-15 | 2008-09-15 | |
| US97023P | 2008-09-15 | ||
| PCT/US2009/056985 WO2010031051A1 (en) | 2008-09-15 | 2009-09-15 | Methods of treatment of hyperuricemia and associated disease states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2521674T3 true ES2521674T3 (es) | 2014-11-13 |
Family
ID=41319433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09792556.4T Active ES2521674T3 (es) | 2008-09-15 | 2009-09-15 | Métodos de tratamiento de hiperuricemia y estados patológicos asociados |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8748496B2 (https=) |
| EP (1) | EP2349280B1 (https=) |
| JP (1) | JP5685192B2 (https=) |
| AR (1) | AR073514A1 (https=) |
| AU (1) | AU2009290612B2 (https=) |
| CA (1) | CA2737163C (https=) |
| ES (1) | ES2521674T3 (https=) |
| TW (1) | TW201016208A (https=) |
| WO (2) | WO2010031051A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
| HUP1200205A3 (en) | 2009-06-25 | 2012-09-28 | Savient Pharmaceuticals | Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy |
| CN102726721A (zh) * | 2011-12-21 | 2012-10-17 | 聂存良 | 一种平衡性的微量元素排铅口服液 |
| US20160303050A1 (en) * | 2015-04-20 | 2016-10-20 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN110234340A (zh) * | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| CN109666687B (zh) * | 2018-12-14 | 2020-08-04 | 艾美科健（中国）生物医药有限公司 | 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998485A (en) | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| CN103301094A (zh) * | 2004-11-17 | 2013-09-18 | 乔安妮·麦克劳林 | 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法 |
| JP2010514772A (ja) * | 2006-12-29 | 2010-05-06 | ノームオクシス インコーポレイテッド | シクリトールおよびその誘導体ならびにその治療用途 |
-
2009
- 2009-09-15 WO PCT/US2009/056985 patent/WO2010031051A1/en not_active Ceased
- 2009-09-15 EP EP09792556.4A patent/EP2349280B1/en active Active
- 2009-09-15 CA CA2737163A patent/CA2737163C/en active Active
- 2009-09-15 TW TW098131051A patent/TW201016208A/zh unknown
- 2009-09-15 US US12/560,113 patent/US8748496B2/en active Active
- 2009-09-15 WO PCT/US2009/057003 patent/WO2010031061A1/en not_active Ceased
- 2009-09-15 JP JP2011527043A patent/JP5685192B2/ja active Active
- 2009-09-15 AU AU2009290612A patent/AU2009290612B2/en active Active
- 2009-09-15 AR ARP090103535A patent/AR073514A1/es unknown
- 2009-09-15 ES ES09792556.4T patent/ES2521674T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010031061A1 (en) | 2010-03-18 |
| CA2737163C (en) | 2019-03-12 |
| CA2737163A1 (en) | 2010-03-18 |
| US8748496B2 (en) | 2014-06-10 |
| AU2009290612A1 (en) | 2010-03-18 |
| JP5685192B2 (ja) | 2015-03-18 |
| AR073514A1 (es) | 2010-11-10 |
| EP2349280A1 (en) | 2011-08-03 |
| EP2349280B1 (en) | 2014-07-30 |
| JP2012502914A (ja) | 2012-02-02 |
| TW201016208A (en) | 2010-05-01 |
| WO2010031051A1 (en) | 2010-03-18 |
| US20100152305A1 (en) | 2010-06-17 |
| AU2009290612B2 (en) | 2015-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2521674T3 (es) | Métodos de tratamiento de hiperuricemia y estados patológicos asociados | |
| Escobedo et al. | Restoration of lymphatic function rescues obesity in Prox1-haploinsufficient mice | |
| Yao et al. | Nifedipine inhibits oxidative stress and ameliorates osteoarthritis by activating the nuclear factor erythroid-2-related factor 2 pathway | |
| EA201070465A1 (ru) | Устройство для управления потоком в органе тела | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| Burton et al. | Hypoxia-reoxygenation; a potential source of placental oxidative stress in normal pregnancy and preeclampsia | |
| BRPI0911923A8 (pt) | dispositivos filamentares para tratamento de defeitos vasculares | |
| CL2007003648A1 (es) | Metodo para el tratamiento o profilaxis de infeccion por circovirus 2 porcino (pcv2) o para la reduccion de los sintomas clinicos asociados a pcv2 en animales que tienen anticuerpos anti-pcv2 y/o que tienen 1 a 22 dias de edad que comprende administr | |
| MX362626B (es) | Métodos para tratar pacientes pediátricos usando dexmedetomidina.. | |
| WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
| Morimatsu et al. | Early and exclusive use of norepinephrine in septic shock | |
| BR112017026660A2 (pt) | composição e kit para tratamento de perda de fluidos que provocam hipotensão e/ou hipovolemia | |
| ECSP10010464A (es) | Uso de ranolazina para el tratamiento de enfermedades cardiovasculares | |
| AR085837A1 (es) | Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer | |
| AR054909A1 (es) | Modulacion de los receptores activados por el proliferador de peroxisomas | |
| RU2009139734A (ru) | Способ прогнозирования сосудистых нарушений у больных с эссенциальной артериальной гипертонией | |
| ES2578729T3 (es) | Agente terapéutico para enfermedades relacionadas con el hígado | |
| CN218651905U (zh) | 一种新型的输尿管膀胱吻合装置 | |
| Solanki et al. | Pedicled gracilis myocutaneous flap for treatment of recalcitrant hidradenitis suppurativa of the groin and perineum | |
| Ishida et al. | Attenuation of bone morphogenetic protein receptor type 2 expression in the pulmonary arteries of patients with failed Fontan circulation | |
| Tanaka et al. | Serum S100B is a useful surrogate marker for long-term outcomes in photochemically-induced thrombotic stroke rat models | |
| Mueller et al. | Mandibular reconstruction with microvascular re-anastomosed fibular free flaps–Two complementary methods of postoperative transplant monitoring | |
| von Preussen et al. | Acne inversa successfully treated with infliximab. | |
| ES2599168T3 (es) | Grelina para promover la recuperación de un animal en tratamiento médico | |
| JP5840193B2 (ja) | 死体保存用注入液 |